

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN YTTTRIUM Y 90 CLIVATUZUMAB TETRAXETAN
PRONUNCIATION klye" va tue' zue mab
THERAPEUTIC CLAIM Treatment of pancreatic cancer

CHEMICAL NAMES

1. Immunoglobulin G1, anti-(human mucin MUC1) (human-mouse monoclonal hPAM4 heavy chain), disulfide with human-mouse monoclonal hPAM4 κ -chain, dimer, 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid conjugate, yttrium-⁹⁰Y chelate
2. Immunoglobulin G1, anti-(Mucin-1 (MUC-1, PEMT, Episialin, Tumor-associated mucin, EMA, H23AG, PUM or CD227)); humanized mouse monoclonal hPAM4 γ 1 heavy chain (222-215')-disulfide with humanized mouse monoclonal hPAM4 κ light chain, dimer (228-228":231-231")-bisdisulfide, substituted (average of 2 to 5 substitutions) on N⁶ of lysyl residus by (4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclodec-1-yl)acetyl (substitutive tetraxetan), (90Y)yttrium(III) chelate

MOLECULAR FORMULA $C_{6496}H_{9952}N_{1716}O_{2014}S_{44} \cdot (C_{16}H_{23}N_4O_7^{90}Y)_n$
MOLECULAR WEIGHT 145.7 kDa (antibody)
TRADEMARK hPAM4-Cide
MANUFACTURER Immunomedics, Inc.
CODE DESIGNATION hPAM4-DOTA, IMMU-107, ⁹⁰hY-PAM4
CAS REGISTRY NUMBER 943976-23-6